Dulaglutide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Dec 1, 2016 → Aug 14, 2017
NCT ID
NCT02973100About Dulaglutide + Placebo
Dulaglutide + Placebo is a phase 2 stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT02973100. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03315780 | Approved | Completed |
| NCT02963766 | Phase 3 | Completed |
| NCT02973100 | Phase 2 | Completed |
| NCT02750410 | Approved | Completed |
| NCT01667900 | Phase 1 | Completed |
| NCT01394952 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes